Cerebrospinal Fluid Levels of Chromogranin A in Parkinson’s Disease and Multiple System Atrophy
| Autor: | Hana Prikrylova Vranova, David Stejskal, Sandra Kurčová, Miroslav Vastik, Michaela Kaiserová, Katerina Mensikova, Monika Chudackova, Petr Kanovsky |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Levodopa endocrine system Parkinson's disease chromogranin A multiple system atrophy Gastroenterology cerebrospinal fluid lcsh:RC321-571 03 medical and health sciences 0302 clinical medicine Cerebrospinal fluid Atrophy Statistical significance Internal medicine medicine lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry 0303 health sciences biology business.industry General Neuroscience Communication 030302 biochemistry & molecular biology Chromogranin A medicine.disease nervous system diseases Potential biomarkers biology.protein Parkinson’s disease Biomarker (medicine) business 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Brain Sciences Brain Sciences, Vol 11, Iss 141, p 141 (2021) |
| ISSN: | 2076-3425 |
| Popis: | Background: Chromogranin A (CgA) and other peptides from the chromogranin–secretogranin family have been recently studied as potential biomarkers of various neurodegenerative diseases, including Parkinson’s disease (PD). Methods: We measured CgA in the cerebrospinal fluid (CSF) of 119 PD patients, 18 multiple system atrophy (MSA) patients, and 31 age-matched controls. We also correlated the values with disease duration and levodopa dose equivalent. Results: In the PD patients, CSF CgA tended to be lower than the control group (median 124.5 vs. 185.2 µg/L; p = 0.057); however, the results did not reach statistical significance. CSF CgA levels in MSA were significantly lower compared to the control group (median 104.4 vs. 185.2; p = 0.014). There was no significant difference in CSF CgA between PD and MSA patients (p = 0.372). There was no association between CSF CgA and disease duration or levodopa dose equivalent in PD or in MSA. Conclusions: We observed a tendency toward lower CSF CgA levels in both PD and MSA compared to the control group; however, the difference reached statistical significance only in MSA. Based on these results, CgA may have potential as a biomarker in PD and MSA, but further studies on larger numbers of patients are needed to draw conclusions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|